Yoshinori Kikuchi

A young pregnant woman with oesophageal cancer who responded to carboplatin plus nab-paclitaxel therapy

Yoshinori Kikuchi, Kazuhisa Yamaguchi, Munehiro Wakabayashi, Naobumi Tochigi et autres

jp (code pays fourni par la source)

Outcomes of Ramucirumab Monotherapy for Advanced Gastric Cancer in a Multi-institutional Cohort Study in Japan

Yoshinori Kikuchi, Sakae Nagaoka, Nobue Futawatari, Muneharu Fujisaki et autres

jp (code pays fourni par la source)

Clinical prognosis factor of ramucirumab monotherapy for advanced gastric cancer

Yoshinori Kikuchi, Sakae Nagaoka, Nobue Futawatari, Muneharu Fujisaki et autres

jp (code pays fourni par la source)

Simultaneous malignant peripheral nerve sheath tumour and malignant melanoma of the anorectal region

Nobuto Yamazaki, Yoshinori Kikuchi, Kimihiko Yoshida, Yasuyuki Miura et autres

jp (code pays fourni par la source)

Comparison of the prognostic effect of taxane regimens combined with ramucirumab before nivolumab for advanced gastric cancer

Yoshinori Kikuchi, Yoko Oshima, Muneharu Fujisaki, Mao Tsuru et autres

jp (code pays fourni par la source)

Investigation of Factors Causing Discontinuation of Anticancer Drugs after Preparation, the Economic Effect of Pharmacists' Confirmation of Laboratory Values before Preparation, and Reuse of Wasted Drugs

Sachiko Yanagino, Yoshinori Kikuchi, Yoshiki Arita, Kazumi Watanabe et autres

Introduction: In some cases, anticancer drugs are wasted for various reasons after preparation, resulting in an economic burden. Therefore, the pharmacists in the study verified laboratory test values before dispensing the drug and determined the financial effect of reusing the wasted drug …

jp (code pays fourni par la source)

Comparison of the Efficacy of Nal-IRI+5FU/LV and S-1 in Patients with Advanced Pancreatic Cancer Refractory to Gemcitabine and Nab-Paclitaxel

Kazuhisa Yamaguchi, Yoshinori Kikuchi, Yusuke Kimura, Susumu Iwasaki et autres

INTRODUCTION: Nanoliposomal irinotecan (nal-IRI) + 5-fluorouracil (FU)/leucovorin (LV) is the new standard second-line therapy for advanced pancreatic cancer (PC). Tegafur, gimeracil, and oteracil potassium (S-1) have been used in advanced PC after gemcitabine (GEM) plus nab-paclitaxel treatment, but the clinical difference between …

jp (code pays fourni par la source)

Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2

Yoshinori Kikuchi, Hideaki Shimada, Fumiyuki Yamasaki, Taku Yamashita et autres

jp (code pays fourni par la source)

Complete response to pembrolizumab plus chemotherapy in a case of unresectable advanced esophageal cancer

Tsuyoshi Ishii, Kazuhisa Yamaguchi, Ai Fujimoto, Yoshinori Kikuchi et autres

A 74-year-old woman visited our hospital with a chief complaint of anterior thoracic discomfort while eating. Esophagogastroduodenoscopy (EGD) revealed two type 2 neoplastic lesions in the 24 cm and 32 cm incisors. Squamous cell carcinoma was observed on histopathological examination. Contrast-enhanced CT …

jp (code pays fourni par la source)

Prognosis of pancreatic cancer with Trousseau syndrome: a systematic review of case reports in Japanese literature

Munehiro Wakabayashi, Yoshinori Kikuchi, Kazuhisa Yamaguchi, Takahisa Matsuda

Trousseau syndrome is a paraneoplastic syndrome associated with a risk of poor prognosis. We reviewed the survival time and prognosis of patients with Trousseau syndrome. We identified 40 cases from 28 reports of Trousseau syndrome due to pancreatic cancer. We analyzed 20 …

jp (code pays fourni par la source)

Clinical practice guidelines for molecular tumor markers, 2nd edition review part 1

Yoshinori Kikuchi, Hideaki Shimada, Yutaka Hatanaka, Ichiro Kinoshita et autres

jp (code pays fourni par la source)

MO7-3 Network meta-analysis of first-line therapy for unresectable, advanced or recurrent biliary tract cancer

Yoshinori Kikuchi, Kazuhisa Yamaguchi, Hideaki Shimada

jp (code pays fourni par la source)